Abstract
The aim of this study was to evaluate pristinamycin in the treatment of MSSA bone and joint infection (BJI). A retrospective, single-centre cohort study (2001-11) investigated outcome in adults receiving pristinamycin for MSSA BJI and pristinamycin-related adverse events (AEs). One hundred and two MSSA BJIs were assessed in 98 patients [chronic infection, 33.3%; and orthopaedic device-related infection (ODI), 67.6%]. Surgery was performed in 77.5% of total cases, and in all but three ODIs, associated with antibiotic therapy of a median total duration of 29.2 weeks. Pristinamycin was prescribed as a part of the initial intensive treatment phase (29.4%) and/or included in final maintenance therapy (83.3%) at a dose of 47.6 (45.5-52.6) mg/kg/day for 9.3 (1.4-20.4) weeks. AEs occurred in 13.3% of patients, consisting of gastrointestinal disorder (76.9%) or allergic reaction (23.1%), leading to treatment interruption in 11 cases. AEs were related to daily dose (OR, 2.733 for each 10 additional mg/kg/day; P = 0.049). After a follow-up of 76.4 (29.6-146.9) weeks, the failure rate was 34.3%, associated with ODI (OR, 4.421; P = 0.006), particularly when the implant was retained (OR, 4.217; P = 0.007). In most patients, the pristinamycin...Continue Reading
References
Nov 1, 1994·Journal of Clinical Epidemiology·M CharlsonJ Gold
Apr 23, 2005·The Journal of Antimicrobial Chemotherapy·John Ng, Iain B Gosbell
Jan 20, 2006·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·J Kent EllingtonRobert Sherertz
Nov 21, 2007·Médecine et maladies infectieuses·UNKNOWN Spilf
Apr 11, 2008·FEMS Microbiology Letters·Marilyn C Roberts
Aug 16, 2008·The Journal of Infection·N RupareliaI Byren
Mar 11, 2009·Clinical Pharmacokinetics·Cornelia B LandersdorferFritz Sörgel
Nov 26, 2009·Médecine et maladies infectieuses·UNKNOWN la Société de Pathologie Infectieuse de Langue Française (SPILF)UNKNOWN Société Française de Rhumatologie (SFR-Rhu)
Jun 16, 2010·Antimicrobial Agents and Chemotherapy·A B ReidK L Buising
May 24, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Benjamin A Lipsky Infectious Diseases Society of America
Jun 15, 2012·Biomaterials·Carla Renata ArciolaJohn William Costerton
Dec 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Douglas R OsmonUNKNOWN Infectious Diseases Society of America
Mar 9, 2013·BMJ Case Reports·Gaud CathoTristan Ferry
Oct 15, 2013·International Journal of Medical Microbiology : IJMM·Yvonne Mast, Wolfgang Wohlleben
Nov 20, 2013·Antimicrobial Agents and Chemotherapy·Florent ValourUNKNOWN Lyon BJI Study Group
Jun 4, 2014·The Journal of Antimicrobial Chemotherapy·Eden C CooperAmanda Gwee
Jan 22, 2015·Antimicrobial Agents and Chemotherapy·Florent ValourFrédéric Laurent
Feb 14, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F ValourUNKNOWN Lyon BJI Study Group
May 29, 2015·Clinical Microbiology Reviews·Steven Y C TongVance G Fowler
Citations
Jul 2, 2016·The Journal of Antimicrobial Chemotherapy·Aiden J Plant, Cressida Auckland
Sep 3, 2016·The Journal of Antimicrobial Chemotherapy·F ValourUNKNOWN Lyon Bone and Joint Infection Study Group
Nov 5, 2016·International Journal of Antimicrobial Agents·Benjamin DavidoAurélien Dinh
Oct 1, 2019·Journal of Orthopaedic Trauma·Melissa DepypereUNKNOWN Fracture-Related Infection (FRI) Consensus Group
Sep 25, 2020·Nature·Qi LiIan B Seiple
Oct 9, 2020·Expert Review of Anti-infective Therapy·Sophie Reissier, Vincent Cattoir